NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Chronic Inflammation as a Key Driver of Long Covid
TL;DR
Soligenix Inc. and similar companies can gain a competitive edge by developing treatments targeting chronic inflammation in long Covid patients.
A new study identifies chronic inflammation as the key driver of long Covid, opening pathways for targeted treatment development.
This discovery offers hope for 15 million Americans suffering from long Covid, potentially improving their quality of life through new treatments.
Chronic inflammation, long known for other conditions, is now revealed as the surprising culprit behind persistent long Covid symptoms.
Found this article helpful?
Share it with your network and spread the knowledge!
The content reports that a new study has established chronic inflammation as the key driver among people with long Covid, which opens new pathways to treating the condition.
According to the Department of Health & Human Services cited in the content, about 15 million individuals in the U.S. live with long Covid.
The scientific community has struggled to understand why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid.
The research serves as a reminder of the long-term effects of chronic inflammation in the body and its potential role in driving long Covid symptoms.
This understanding could benefit the approximately 15 million Americans with long Covid by opening new treatment pathways, and companies like Soligenix Inc. that are investing resources in related research.
BioMedWire is a specialized communications platform focused on the latest developments in Biotechnology, Biomedical Sciences and Life Sciences sectors, providing wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications solutions.
To receive SMS alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only).
For more information, visit https://www.BioMedWire.com, and for terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
Curated from InvestorBrandNetwork (IBN)
